Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Placebo controlled study of rosiglitazone in HIV lipoatrophy.

Trial Profile

Placebo controlled study of rosiglitazone in HIV lipoatrophy.

Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Atherosclerosis; Hyperlipidaemia
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 02 Mar 2010 Actual end date (December 2008) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 May 2008 The expected completion date for this trial is now 1 Apr 2009 (source: ClinicalTrials.gov).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top